Cowen & Co. analyst Yaron Werber maintained a Buy rating on Exelixis (EXEL) yesterday and set a price target of $29. The company’s shares opened today at $22.32.
According to TipRanks.com, Werber is ranked #383 out of 5203 analysts.
Currently, the analyst consensus on Exelixis is a Strong Buy with an average price target of $29.86, which is a 33.8% upside from current levels. In a report issued on February 13, Oppenheimer also maintained a Buy rating on the stock with a $31 price target.
See today’s analyst top recommended stocks >>
Based on Exelixis’ latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $360 million. In comparison, last year the company had a net profit of $38.49 million.
Based on the recent corporate insider activity of 85 insiders, corporate insider sentiment is negative on the stock. Earlier this month, Stelios Papadopoulos, a Director at EXEL sold 26,250 shares for a total of $557,813.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic.
